Kidney Transplant – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

 A kidney transplant is a surgical procedure in which a healthy kidney from either a living or deceased donor is placed into the lower abdomen. Transplantation is the kidney replacement therapy for suitable patients with end-stage kidney disease (ESKD). In 2020, a record 25,500 kidney transplants were performed in the US. Approximately 72% of these transplants were completed on deceased donors. Transplant recipients were 61% men, and half had diabetes mellitus (30.1%) or hypertension (20.0%) as the listed cause of ESKD, with glomerulonephritis (17.5%) and cystic renal disease (12.8%) being less common. The average kidney transplant will cost $450,000 in 2020. Charges for transplant admission, including surgery, are the most expensive line item, accounting for 34% of total costs. Despite rising medication costs, immunosuppression and other transplant-related drugs such as prophylactic antibiotics account for only 7% of total charges (from transplant to 6 months post-transplant).

 

The competitive landscape of Kidney Transplant includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Kidney Transplant across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Kidney Transplant Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Kidney Transplant – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          MDR-101          Medeor Therapeutics, Inc.         Phase 3

2          Imlifidase          Hansa Biopharma AB    Phase 3

3          glecaprevir/pibrentasvir  AbbVie  Phase 3

4          Zampilimab       UCB Pharma    Phase 2

5          Zepatier            Merck Sharp & Dohme Corp.     Phase 2

6          Pegcetacoplan  Apellis Pharmaceuticals, Inc.     Phase 2

7          Eledon Pharmaceuticals Aurinia Pharmaceuticals Inc.      Phase 2

8          Darbepoetin alfa            Hoffmann-La Roche      Phase 3

9          NPC-21 Nobelpharma    Phase 2

10        FR104  OSE Immunotherapeutics          Phase 2

Continued